These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33290989)

  • 1. Hub gene identification and prognostic model construction for isocitrate dehydrogenase mutation in glioma.
    Jia Y; Yang W; Tang B; Feng Q; Dong Z
    Transl Oncol; 2021 Jan; 14(1):100979. PubMed ID: 33290989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative analysis of CBR1 as a prognostic factor associated with IDH-mutant glioblastoma in the Chinese population.
    Ji P; Shan X; Wang J; Zhang P; Cai Z
    Am J Transl Res; 2022; 14(8):5394-5408. PubMed ID: 36105052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
    Karsy M; Guan J; Huang LE
    J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular classification of IDH-mutant glioblastomas based on gene expression profiles.
    Wu F; Chai RC; Wang Z; Liu YQ; Zhao Z; Li GZ; Jiang HY
    Carcinogenesis; 2019 Jul; 40(7):853-860. PubMed ID: 30877769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma.
    Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long Non-coding RNA Expression Profiling Identifies a Four-Long Non-coding RNA Prognostic Signature for Isocitrate Dehydrogenase Mutant Glioma.
    Chen Y; Guo Y; Chen H; Ma F
    Front Neurol; 2020; 11():573264. PubMed ID: 33329315
    [No Abstract]   [Full Text] [Related]  

  • 7. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
    Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW
    Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Expression Profiling Stratifies IDH-Wildtype Glioblastoma With Distinct Prognoses.
    Liu YQ; Wu F; Li JJ; Li YF; Liu X; Wang Z; Chai RC
    Front Oncol; 2019; 9():1433. PubMed ID: 31921684
    [No Abstract]   [Full Text] [Related]  

  • 11. IGFBP2 expression predicts IDH-mutant glioma patient survival.
    Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
    Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma.
    Joo B; Han K; Ahn SS; Choi YS; Chang JH; Kang SG; Kim SH; Zhou J; Lee SK
    Eur Radiol; 2019 Dec; 29(12):6643-6652. PubMed ID: 31175415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis.
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
    Eur Radiol; 2019 Feb; 29(2):745-758. PubMed ID: 30003316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
    Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
    Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
    Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Liu X; Li Y; Li S; Fan X; Sun Z; Yang Z; Wang K; Zhang Z; Jiang T; Liu Y; Wang L; Wang Y
    Aging (Albany NY); 2019 Jan; 11(2):673-696. PubMed ID: 30696801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
    Spino M; Kurz SC; Chiriboga L; Serrano J; Zeck B; Sen N; Patel S; Shen G; Vasudevaraja V; Tsirigos A; Suryadevara CM; Frenster JD; Tateishi K; Wakimoto H; Jain R; Riina HA; Nicolaides TP; Sulman EP; Cahill DP; Golfinos JG; Isse K; Saunders LR; Zagzag D; Placantonakis DG; Snuderl M; Chi AS
    Clin Cancer Res; 2019 Feb; 25(4):1261-1271. PubMed ID: 30397180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A four-protein expression prognostic signature predicts clinical outcome of lower-grade glioma.
    Patil V; Mahalingam K
    Gene; 2018 Dec; 679():57-64. PubMed ID: 30077762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of RNA: 5-Methylcytosine Methyltransferases-Related Signature for Predicting Prognosis in Glioma.
    Wang P; Wu M; Tu Z; Tao C; Hu Q; Li K; Zhu X; Huang K
    Front Oncol; 2020; 10():1119. PubMed ID: 32974125
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas.
    Qian Z; Li Y; Fan X; Zhang C; Wang Y; Jiang T; Liu X
    Oncoimmunology; 2018; 7(6):e1434466. PubMed ID: 29872572
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.